Trial · NCT00556374
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to First Clinical Fracture | Placebo | NA | 95% Confidence Interval NA to NA | Days | |
| Time to First Clinical Fracture | Denosumab | NA | 95% Confidence Interval NA to NA | Days | |
| Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites | Placebo | -2.75 | 95% Confidence Interval -3.44 to -2.07 | Percent Change in BMD | |
| Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites | Denosumab | 7.27 | 95% Confidence Interval 6.56 to 7.98 | Percent Change in BMD | |
| Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites | Placebo | -3.32 | 95% Confidence Interval -4.06 to -2.58 | Percent Change in BMD | |
| Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites | Denosumab | 4.60 | 95% Confidence Interval 3.85 to 5.35 | Percent Change in BMD | |
| Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites | Placebo | -3.10 | 95% Confidence Interval -3.72 to -2.48 | Percent Change in BMD | |
| Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites | Denosumab | 3.41 | 95% Confidence Interval 2.78 to 4.04 | Percent Change in BMD | |
| Number of Participants With New Vertebral Fractures | Placebo | 49 | Participants | ||
| Number of Participants With New Vertebral Fractures | Denosumab | 27 | Participants | ||
| Number of Participants With New or Worsening Vertebral Fractures | Placebo | 55 | Participants | ||
| Number of Participants With New or Worsening Vertebral Fractures | Denosumab | 31 | Participants | ||
| Disease-free Survival (DFS) | Placebo | NA | 95% Confidence Interval NA to NA | Days | |
| Disease-free Survival (DFS) | Denosumab | NA | 95% Confidence Interval NA to NA | Days | |
| Bone Metastases-free Survival (BMFS) | Placebo | NA | 95% Confidence Interval NA to NA | Days | |
| Bone Metastases-free Survival (BMFS) | Denosumab | NA | 95% Confidence Interval NA to NA | Days | |
| Overall Survival (OS) | Placebo | NA | 95% Confidence Interval NA to NA | Days | |
| Overall Survival (OS) | Denosumab | NA | 95% Confidence Interval NA to NA | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00556374/results